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Opinion statement
Patients with suspected or confirmed osteosarcoma should be evaluated and treated at
a comprehensive cancer center within a multidisciplinary sarcoma program that in-
cludes pediatric, medical and radiation oncologists, orthopedic and surgical oncolo-
gists, musculoskeletal pathologists, and radiologists. Successful treatment involves
proper diagnosis, neoadjuvant and adjuvant multi-agent chemotherapy, and aggres-
sive surgery with an emphasis toward limb-preserving procedures. Treatment of
osteosarcoma should be undertaken within the framework of large cooperative group
clinical trials for children, adolescents, and adults. Patients treated with osteosarcoma
should be followed closely both for recurrence of disease and for development of late
effects of the treatment of their cancer. The treatment of metastatic, recurrent and/or
refractory disease is more controversial. Despite advances in systemic treatment,
surgical technique, and supportive care, the overall outcome is still poor.
Introduction
Osteosarcoma is the most common primary malignant
neoplasm of bone in children and adolescents. It is
characterized by the proliferation of malignant mes-
enchymal cells that are capable of producing osteoid or
immature bone [1]. Although rare, with only 400 new
cases diagnosed per year in the United States, osteo-
sarcoma represents the sixth most common malig-
nancy in adolescents and young adults [2]. Prior to
1970, the overall prognosis for patients with osteosar-
coma was dismal with a 10%–20% overall survival rate
for patients with localized disease treated with aggres-
sive surgery. Over the past 30–40 years with the intro-
duction of neoadjuvant and adjuvant systemic
chemotherapy, the survival has increased dramatically
to about 65%–75% for patients without clinically evi-
dent metastatic disease at presentation [3]. The
improvements in chemotherapy have been paralleled
by improvements in surgical techniques that achieve
local control with limb-sparing procedures, and
improvements in diagnostic and imaging techniques.
This chapter will review the current multidisci-
plinary treatment of osteosarcoma and recent devel-
opments in the management of this aggressive
neoplasm, as well as stress the importance of treating
and evaluating patients with osteosarcoma within a
multidisciplinary sarcoma program or cancer center
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that offers comprehensive care through the input and
contributions of pediatric, medical, and radiation
oncologists, orthopedic and surgical oncologists, and
musculoskeletal pathologists and radiologists.
Clinical presentation, diagnostic evaluation, and biopsy
• The vast majority of patients with osteosarcoma present with localized
pain at the primary tumor site. The most commonly affected bones are
the metaphyseal region of long bones such as the distal femur,
proximal tibia, and proximal humerus although osteosarcoma can
arise in any bone in the body [4]. A detailed history with a complete
physical exam should be performed prior to any evaluation. Physical
examination may reveal the presence of a tender and firm soft tissue
mass at the primary site. If a diagnosis of osteosarcoma or another
malignant bone or soft tissue tumor is suspected, the patient should
be transferred to a comprehensive cancer center with a multidisci-
plinary sarcoma program for further evaluation and treatment. Lab-
oratory evaluation is generally normal. However, serum alkaline
phosphatase and lactate dehydrogenase levels have been reported
elevated in 30%–40% of patients and have been associated with a
poorer prognosis [5,6].
• Plain radiographic films are usually the first diagnostic imaging study
undertaken and should include the entire affected bone. The classical
appearance of osteosarcoma on plain films shows destruction of the
normal trabecular bone with presence of a Codman’s Triangle formed
by new periosteal formation and elevation of the cortex [7]. CT and
MRI scanning are used to delineate the extent of the primary tumor
and planning of definitive surgery. MRI is particularly useful to
determine the intra and extraosseous extent, soft tissue, and contigu-
ous structure involvement of the tumor. Care again must be taken to
image the entire involved bone. Metastatic evaluation at diagnosis
should include a Chest CT scan to detect pulmonary metastasis. Nu-
clear medicine imaging techniques are being used increasingly to aid
in the initial staging/metastatic evaluation and response to therapy.
Technetium–99-m bone scans are a standard part of the metastatic
evaluation as they are very sensitive in detecting bony metastases,
present in 10% of patients with osteosarcoma [8]. 18-Fluorodeoxy-
glucose Positron emission tomography(18FDG-PET) with or without
the combination of a whole body CT is also being increasingly used in
the initial staging and treatment monitoring although a clear benefit
has not been demonstrated [9,10]. A consensus on the imaging
guidelines for children, adolescents and young adults with osteosar-
coma has been put forward by the Children’s Oncology Group (COG)
[11•].
• Tissue biopsy of osteosarcoma must be obtained to confirm the
diagnosis even though radiographic imaging is highly suggestive. The
biopsy should be carefully planned with multidisciplinary input from
the musculoskeletal radiologist, pathologist, and orthopedic and
surgical oncologists so as to ensure the feasibility of procedure, the
adequacy of specimen, and above all to maintain the viability of a
definitive surgery with possibility of limb salvage. At our institution,
we find that CT-guided core biopsies performed by a skilled inter-
ventional musculoskeletal radiologist will yield the diagnosis the
majority of the time. The advantage of CT-guided core biopsy is that
this can often be done more rapidly and require only local anesthesia
versus an open biopsy. Multiple large core needle biopsies are often
necessary to yield enough tissue to make the diagnosis and consider
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differential diagnoses with sufficient tissue for immunostains and
cytogenetic studies. Core biopsy at our institution approaches 95%
accuracy in establishing a diagnosis, and is our diagnostic method of
choice. However, the decision to utilize CT-guided biopsy versus open
biopsy should be made on a case by case basis as a 25% non-diag-
nostic rate has been reported by other institutions [12]. When a core
biopsy is either non-diagnostic or not technically possible, an open
biopsy can be performed. The principles of open biopsy for osteo-
sarcoma and other malignant bone tumors is to obtain adequate tis-
sue without jeopardizing opportunity for limb salvage by
contaminating tissue with malignant cells, and should be performed
by a skilled orthopedic or surgical oncologist. The biopsy should be
performed with a longitudinal incision so that the entire biopsy tract
can be excised during later surgery, and careful hemostatic control
should be attained to minimize the development of a hematoma
contaminated with malignant cells [13].
Systemic therapy
• Prior to the introduction of adjuvant systemic chemotherapy the
overall survival of osteosarcoma was less than 20% with the majority
of patients developing metastatic disease presumably from the pres-
ence of microscopic subclinical metastatic disease present at the time
of diagnosis[14]. With modern multimodality therapy combining
systemic chemotherapy and complete surgery, the cure rate now ap-
proaches over 70% for patients with non-metastatic osteosarcoma
[15].
• Many trials investigating adjuvant chemotherapy in osteosarcoma
patients have been performed in the past 30 years. Some of the
notable trials over the past 10 years are summarized in Table 1. Initial
efforts defined active agents as high-dose methotrexate with leucovo-
rin rescue, doxorubicin, cisplatin, and ifosfamide with or without
etoposide [16–20•]. The development of combination chemotherapy
with administration of the aforementioned active agents has been
mostly empiric though is now the cornerstone of chemotherapy.
• The initial rationale for administering neoadjuvant chemotherapy was
based on the development of limb-salvage procedures. Originally,
limb-salvage endoprostheses were custom made taking several weeks
to months to manufacture. Neoadjuvant therapy was employed as a
means of bridging the gap from biopsy to resection [21,22]. However,
it had been suggested that neoadjuvant therapy might improve sur-
vival as well as improve limb-salvage rates. A randomized study
(POG–8651) conducted by the Pediatric Oncology Group from 1986
to 1993 compared immediate surgery followed by post-operative
chemotherapy versus presurgical chemotherapy followed by surgery.
The event-free survival (EFS) was similar in both groups: 65% for
immediate surgery and 61% for neoadjuvant therapy with similar
incidence of limb salvage (50%–55%) in both [23••]. Another
rationale for using neoadjuvant chemotherapy is the capability of
individualizing therapy based on tumor response. It has been reported
from numerous trials that histologic response with tumor necrosis
greater than 90% confers a better prognosis [22–26••]. The strategy of
intensifying or altering post-operative therapy based on poor tumor
necrosis has been used successfully in the 1980s by investigators at the
Memorial Sloan Kettering Cancer Center on the T10 trial and later
confirmed by the Rizzoli Institute [27,28]. However, the impressive
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results on these trials improving the overall outcome of ‘‘poor
responders’’ by tailoring post-operative therapy were not duplicated in
other large cooperative group studies [25,29,30]. The question of
intensification and individualization of therapy based on tumor
necrosis is currently being investigated in the current large cooperative
trial through the European and American Osteosarcoma Group
(EURAMOS1, AOST0331, ClinicalTrials.gov/NCT00134030) a multi-
national collaboration of the COG, Cooperative Osteosarcoma Group
(COSS), the Scandinavian Sarcoma Group (SSG), and the European
Osteosarcoma Intergroup (EOI). Patients with poor necrosis are ran-
domized to receive high-dose methotrexate, doxorubicin, cisplatin,
with or without the addition of ifosfamide and etoposide. On the
other hand, patients with a good response will continue high-dose
methotrexate, cisplatin, and doxorubicin are then randomized to a
maintenance arm with pegylated interferon alpha. Currently, over
1000 patients have been enrolled on this trial as of January 2009.
• The addition of ifosfamide with or without etoposide to 3 drug regi-
mens of high-dose methotrexate, cisplatin, and doxorubicin in the
treatment of primary localized osteosarcoma is controversial. Several
groups have obtained favorable results with ifosfamide containing
regimens. However, in a recent large randomized controlled American
collaborative trial (INT–0133) the addition of ifosfamide to standard
therapy was investigated as well as the addition of the immuno-
modulator muramyl-tripeptide-ethanolamine (MTP-PE). The addition
of ifosfamide did not affect overall survival or EFS. Although the
addition of MTP-PE did result in a statistically significant improve-
ment in overall survival (78% vs 70%) [31••]. The standard use of
MTP-PE will likely be the subject of future confirmatory trials.
Surgical management
• Over the last 30 years, advances in chemotherapy, imaging, surgical
technique, and biomaterial engineering have ushered in a new era of
surgical management for osteosarcoma. The basic tenet for the treat-
ment of osteosarcoma is that complete resection is a prerequisite for
cure [24]. Whereas radical resection by amputation was the mainstay
of therapy into the 1970s, currently more than 85% of patients un-
dergo wide resection with limb-sparing surgery [36]. Although no
randomized studies have been done, large retrospective studies have
Table 1. Selected recent large studies of chemotherapy for localized osteosarcoma
Study Protocol Years conducted Patients, n Chemotherapy OS/EFS
COSS-86 [32] 1986–1988 171 DOXO, MTX, CDDP, ±IFOS 72%/66%
POG-8651 [23••] 1986–1993 100 DOXO, BCD, CDDP 78%/65%
IOR-OS4 [33] 1993–1995 133 DOXO, MTX, CDDP, IFOS 71%/56%
INT–0133, CCG-7921,
POG-9351 [31••]
1993–1997 662 DOXO, MTX, CDDP, ±IFOS, ±MTP 78%/67% for MTP arm.
EOI-3 [34••] 1993–2002 497 DOXO, CDDP, ±GCSF 56%/40%
ISG/SSG-1 [35•] 1997–2000 182 DOXO, MTX, CDDP, IFOS 77%/64%
COSS—Cooperative Osteosarcoma Study Group, POG—Pediatric Oncology Group, IOR—Istituto Ortopedico Rizzoli, CCG—Children’s Cancer
Group, EOI—European Osteosarcoma Intergroup, ISG/SSG—Italian Sarcoma Group/Scandinavian Sarcoma Group, DOXO—Doxorubicin,
MTX—Methotrexate, CDDP—Cisplatin, IFOS—ifosfamide, BCD—bleomycin, cytoxan, actinomycin D, GCSF—granulocyte colony-stimulating
factor.
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shown no survival advantage to amputation over limb-salvage pro-
cedures [37,38]. Negative surgical margins (defined as at least 1 cm in
bone with 2–5 cm recommended) and tumor responsiveness are di-
rectly associated with local recurrence. In patients with marginal
resections and with tumor necrosis less than 90% after preoperative
chemotherapy, local recurrence has been reported as high as 30%
[39]. Therefore, limb salvage is recommended when adequate surgical
margins can be achieved. Only surgeons with adequate experience
should perform limb-preserving procedures [40].
• Reconstructive options for limb-salvage surgery include autogenous
bone grafts (vascularized or devascularized), structural bone grafts
(osteoarticular and intercalary), and metallic endoprosthetics. The
technique selected is a function of the location of the tumor, age of
the patient, and types of adjuvant therapies that will be employed, as
well as the surgeon’s comfort level with a particular procedure. Our
institution primarily utilizes endoprosthetic reconstruction. We have
reported low rates of infection, mechanical failure, revision, and local
recurrence with this technique [41,42]. Significant improvements in
biomaterial engineering over the past 20 years including circumfer-
ential porous coating, modular components, and hydroxyapatite-
coating have led to excellent outcomes [43]. Most recently, exciting
data is emerging on the Compress implant, an endoprosthesis de-
signed to mitigate complications of aseptic loosening by preventing
stress shielding and particle-induced osteolysis through compressive
forces at the bone-implant interface [44].
• A unique challenge in reconstruction after osteosarcoma resection in
the pediatric population is the issue of limb growth. Prior to the
advent of extendable prostheses, a complex surgical procedure was
required to replace one modular component with a longer one [45].
More sophisticated lengthening systems have entered the market
including the redesigned Phenix prosthesis (Phenix Medical, Paris,
France), which uses an electromagnet outside the body to heat a tube
of plastic inside the prosthesis, thus expanding an internal spring [46].
A British endoprothesis (Stanmore Implants Worldwide, United
Kingdom) uses an external rotating magnetic field to induce a magnet
embedded in the prosthesis to rotate and power a small motor that
elongates the prosthesis [36]. While these technologies are still in
development and are expensive, they hold great promise for the future
of endoprosthetic reconstruction as they eliminate the need for sub-
sequent surgeries in skeletally immature patients.
Radiation therapy
• Osteosarcoma is a relatively radioresistant malignancy. For this rea-
son, adjuvant chemotherapy and surgery have been the mainstays of
therapy. Prophylactic whole lung irradiation was used in the late
1970s as a means of reducing lung metastases post-operatively
[47,48]. However, the addition of prophylactic lung irradiation has
not demonstrated a clear advantage over adjuvant chemotherapy [49].
• Radiation therapy in the primary local control setting should be re-
served on a case-by-case basis for patients with unresectable tumors
and/or where margins of resection are positive [50,51]. Typically these
tumors involve the head and neck or spinal region. For definitive
radiation therapy, doses of 55–60 Gy are given with conventional
daily fractionation of 1.8 Gy.
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• The use of radiation therapy in the treatment of osteosarcoma may
need to be re-investigated with modern radiation delivery techniques
such as intensity modulated radiation therapy and proton beam
therapy where the delivery of radiation to a target volume is improved
while scatter to surrounding organs can be minimized [52]. At our
institution, we have used stereotactic radiosurgery to treat small un-
resectable primary tumors and unresectable metastases usually to the
brain and spinal cord.
• Radiation therapy can be used as an effective palliative measure par-
ticularly for painful bony metastases. Samarium–153 ethylene dia-
mine tetramethylene phosphonate (153Sm-EDTMP) is a bone-seeking
radiopharmaceutical that was approved by the United States Food and
Drug Administration in 1998 for palliation of bone metastases [53].
Standard dose (1 mCi/kg) and high-dose 153Sm-EDTMP (30 mCi/
kg) have been used with palliative benefit for patients with osteosar-
coma and skeletal metastases [54,55]. However, autologous stem cell
rescue is necessary due to myeloablation with high doses of 153Sm-
EDTMP.
Management of recurrent and/or metastatic osteosarcoma
• In contrast to the 60%–70% long-term survival of patients who
present with localized osteosarcoma, patients with clinically evident
metastatic disease at diagnosis have a poor prognosis. About 20% of
patients will present with metastatic osteosarcoma, and the overall
survival is reported from 10% to 50% [56••,57•]. There is no standard
approach for treatment of patients with metastatic disease at diagnosis
despite multiple clinical trials. Combination chemotherapy with
doxorubicin, ifosfamide, etoposide, cisplatin, and high-dose metho-
trexate are currently used at our institution for treatment. A Pediatric
Oncology Group Trial with high-dose ifosfamide and etoposide
induction therapy followed by adjuvant high-dose methotrexate,
doxorubicin, and cisplatin chemotherapy with lower dose ifosfamide
and etoposide had a 59% overall response rate with a 2 year projected
survival of 39% for lung only and 58% for bone only involvement
[20]. Although these results appear to be superior, the long-term
survival data have not been reported. In most studies, however, pa-
tients with bony metatases fared poorly versus those with pulmonary
metastases, and survival appears to inversely correlate with the num-
ber of metastases [56,58]. Notwithstanding that there is no standard
for treatment of metastatic disease at diagnosis, we recommend
aggressive multi-agent chemotherapy, primary local control, and
metastasectomy if possible.
• A total of 30%–40% of patients with localized osteosarcoma will
develop a recurrence in spite of incredibly aggressive chemotherapy
and surgery. In several large series, the 5-year survival has been re-
ported between 23% and 29% [59,60•], and complete surgery was
required to achieve cure. In both studies, survival also correlated with
the number of metastases at the time of recurrence as well as the
recurrence-free interval. Patients with pulmonary metastases should
have resection of disease by a skilled thoracic surgeon. Bilateral pul-
monary disease is not a contraindication to resection and these pa-
tients should have staged thoracotomies. The use of chemotherapy in
the adjuvant setting for metastatic osteosarcoma continues to be
studied. Although controversial, many centers including ours advocate
use of adjuvant chemotherapy when there is a solitary lung recurrence
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occurring less than 24 months from initial diagnosis, and a period of
close observation for greater than 24 months from initial diagnosis
[61,62]. Ifosfamide with or without etoposide is the favored salvage
regimen. As there is no standard other than complete surgical me-
tastasectomy, the decision of adjuvant chemotherapy is made on an
individual basis. Hence, it is of paramount importance that a skilled
thoracic oncologic surgeon be involved in the management of these
patients.
• Other therapeutic approaches to the management of metastatic and/
or recurrent disease are mentioned elsewhere in this review, and in-
clude radiation to sites of metastases, Samarium–153, bisphospho-
nates, and other new promising investigational agents currently in
clinical trials (Table 3).
Surveillance
• Judicial surveillance for recurrence is required in all patients with
osteosarcoma. At our institution we generally follow the recently
published recommended guidelines from the Children’s Oncology
Group Bone Tumor Committee [11]. Patients are screened for recur-
rence for 10 years after therapy is completed. The guidelines for sur-
veillance post-chemotherapy are summarized in Table 2. It is
important that careful attention be paid to cumulative radiation doses
and that the ALARA (as low as reasonably achievable) principle is
utilized for imaging associated radiation in particular for PET/CT
scans, which can confer a substantial amount of whole body radiation
for pediatric patients [63].
Late effects
• Clearly, tumor recurrence is the most significant problem for patients
with osteosarcoma. However, as the overall survival of patients with
osteosarcoma has improved over the last several decades, the long-
Table 2. Recommended guidelines for tumor directed surveillance [11]
Site Imaging Frequency/Duration
Primary AP and lateral radiographs Every 3 months 9 2 years,
Every 6 months 9 3 years,
Every 12 months 9 5 years
MRI with gadolinium and/or CT with contrast If abnormal imaging or symptoms
Chest CT non-contrast Every 3 months 9 2 years,
Every 6 months 9 3 years,
Every 12 months 9 5 years
AP and lateral radiographs Every 12 months 9 5 years after last CT
Bone metastases AP and lateral radiographs Every 3 months 9 2 years,
Every 6 months 9 3 years,
Every 12 months 9 5 years
MRI with gadolinium and/or CT with contrast If abnormal imaging or symptoms
Whole body (99 m)Tc-MDP Bone Scan If abnormal imaging or symptoms
Whole body FDG-PET If abnormal imaging or symptoms and
PET positive on prior scan
AP—anterior posterior; MRI—magnetic resonance imaging; CT—computerized tomography; 99 mTc-MDP—99 m technetium methylene
disphosphonate; FDG-PET—fluorodeoxyglucose positron emission tomography.
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term side effects of treatment have become more evident. Aside from
the recurrence of primary cancer, another worrisome long-term con-
sequence is the development of a secondary malignancy. The inci-
dence of a second malignancy in several large retrospective cohorts
has been reported between 2.2% and 3.4% [64–66]. Leukemia was
most prevalent followed by breast, soft tissue, lung, kidney, central
nervous system, and other cancers.
• The long-term effects of therapy for osteosarcoma are numerous,
potentially life threatening and debilitating. Although relatively
infrequent, anthracycline-induced cardiac toxicity can be fatal. Careful
observation of cumulative anthracycline dosage, avoidance of rapid
infusion [67], and surveillance of cardiac function with routine serial
echocardiography or multi-gated acquisition (MUGA) scans should be
part of routine practice. Evidence supporting the use of cardiopro-
tective agents such as dexrazoxane is debatable [68] and we recom-
mend using dexrazoxane on an individual basis for patients with high
risk of developing cardiac effects.
• Other late sequelae include, but are not limited to, nephrotoxicity
from ifosfamide and cisplatin, ototoxicity from cisplatin, and male
infertility likely from ifosfamide [69, 70].
• We recommend life-long screening for late sequelae at a compre-
hensive cancer center with an established long-term follow up or
cancer survivorship program.
Emerging therapies
• Over the past several decades, new chemotherapeutic agents have
been added to the armamentarium of anticancer drugs. However, few
agents have shown activity or clinical benefit in osteosarcoma. Com-
bination therapy with gemcitabine and docetaxel in refractory bone
sarcomas was well tolerated and demonstrated antitumor activity [71].
• Immune approaches to osteosarcoma therapy continue to be investi-
gated. Immunotherapy has been utilized in the therapy for osteosar-
coma for several decades notably with the administration of
interferon-alpha [72]. The effect of maintenance pegylated interferon
alpha is currently being studied in the EURAMOS1 trial in patients
with a good response to neoadjuvant chemotherapy. Another ap-
proach has been to use the immuno-stimulant muramyl-tripeptide
phosphatidyl-ethanolamine (MTP-PE), which is derived from Bacille
Calmette-Guerin and is a potent macrophage activator. Recently,
addition of liposomal MTP-PE in combination with adjuvant che-
motherapy resulted in a statistically significant increase in overall
survival (78% OS) versus standard combination chemotherapy (70%
OS) [31]. Other immune strategies have focused on generating T-cell
responses by vaccination with the anti-idiotypic antibody mimicking
CD55, a complement regulatory protein expressed by many solid tu-
mors including osteosarcoma [73, 74]. The use of dendritic cell vac-
cines to enhance cytotoxic T-cell activation is being evaluated in
xenograft models as well.
• Small molecule therapy with inhibition of the Src kinase pathway
involved in osteoclast activity has been shown to have anti-prolifer-
ative and pro-apoptotic activity in osteosarcoma cell lines and xeno-
graft models [75, 76]. The orally available Src tyrosine kinase inhibitor
AZD0530 is currently being investigated in a phase II clinical trial in
osteosarcoma with pulmonary recurrence post-metastasectomy con-
ducted by the Sarcoma Alliance Research through Collaboration
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(SARC) global cooperative network (SARC012, NCT00752206).
Other recent trials using small molecule biologic therapy have focused
on targeting the insulin like growth factor receptor (IGFR) with the
monoclonal antibody R1507 (SARC011, NCT00615680) expressed in
osteosarcoma and other sarcomas as well as targeting HER–2 with the
monoclonal antibody trastuzumab overexpressed in 30%–40% of
osteosarcoma tumors (COG-AOST0121, NCT00023998, study com-
pleted). A summary of selected current open trials for osteosarcoma is
listed in Table 3.
Summary
• The prognosis of localized osteosarcoma has improved dramatically
over the past 30 years with multi-modality treatment of aggressive
surgery and combination chemotherapy. Despite these advances for
localized disease and with the development of newer chemothera-
peutic agents, the prognosis for metastatic, refractory and recurrent
osteosarcoma is still dismal. Multidisciplinary management within a
comprehensive cancer center is extremely important to the diagnosis,
medical, surgical, and overall care of patients with osteosarcoma. A
concerted effort should be made to treat osteosarcoma within the
scope of a large international collaborative trial such as the EURA-
MOSI trial. For patients that have completed treatment, oncologists
must be particularly attentive to long-term surveillance for recurrence
and development of late-effects from chemotherapy. Finally, a con-
tinued emphasis should be placed on preclinical basic science and
translational research aimed at furthering our understanding of oste-
osarcoma with the ultimate goal of providing patients new, molecu-
larly targeted therapies.
Table 3. Select current trials for treatment of osteosarcoma
Trial name Phase ID, Status
Combination chemotherapy, PEG-interferon
alfa-2b, and surgery in treating patients with osteosarcoma
III COG-AOST0331, NCT00134030,
MRC-EURAMOS1, Active
A study of R1507 in recurrent or refractory sarcomas II NCT00615680, SARC011, active
A placebo-controlled study of AZD0530 in patients
with recurrent osteosarcoma localized to the lung
II SARC012, NCT00752206 Approved,
not yet active
Evaluation of zoledronic acid as a single agent or
as an adjuvant to chemotherapy in high grade osteosarcoma
II/III NCT00691236, Active
A study of bevacizumab in combination with chemotherapy
for treatment of osteosarcoma
III NCT00667342, Active
Inhalation SLIT cisplatin for the treatment of osteosarcoma
metastatic to the lung
I/II NCT00102531, Active
Deforolimus in treatment of sarcoma—SUCCEED
(Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus)
III NCT00538239, Active
Trial of dasatinib in advanced sarcomas II SARC009 NCT00464620, Active
A study to determine the activity of SCH 717454 in subjects with
relapsed osteosarcoma or Ewing’s sarcoma (Study P04720)
II NCT00617890, Active
High dose methotrexate with leucovorin rescue with or without
glucarpidase in osteosarcoma
II NCT00634322, Active
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